Senti Biosciences (NASDAQ:SNTI) Posts Earnings Results, Misses Estimates By $0.08 EPS

Senti Biosciences (NASDAQ:SNTI) posted its quarterly earnings data on Friday. The company reported ($0.41) EPS for the quarter, missing analysts’ consensus estimates of ($0.33) by ($0.08), FiscalAI reports. The firm had revenue of $0.02 million during the quarter.

Senti Biosciences Trading Up 16.9%

Shares of SNTI opened at $0.45 on Friday. The stock has a market cap of $13.98 million, a PE ratio of -0.25 and a beta of 2.10. Senti Biosciences has a 1 year low of $0.33 and a 1 year high of $2.88. The stock has a 50 day simple moving average of $0.73 and a 200-day simple moving average of $0.87.

Wall Street Analysts Forecast Growth

Several research firms have issued reports on SNTI. Chardan Capital raised their price target on shares of Senti Biosciences from $11.00 to $12.00 and gave the stock a “buy” rating in a research report on Friday, May 15th. Weiss Ratings restated a “sell (e+)” rating on shares of Senti Biosciences in a research note on Friday, July 17th. One research analyst has rated the stock with a Strong Buy rating, two have assigned a Buy rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, Senti Biosciences currently has a consensus rating of “Moderate Buy” and an average price target of $10.00.

Institutional Investors Weigh In On Senti Biosciences

Large investors have recently made changes to their positions in the company. Armistice Capital LLC acquired a new position in Senti Biosciences in the second quarter worth $1,883,000. Geode Capital Management LLC boosted its holdings in Senti Biosciences by 395.6% in the second quarter. Geode Capital Management LLC now owns 147,314 shares of the company’s stock valued at $311,000 after acquiring an additional 117,588 shares during the last quarter. Citadel Advisors LLC acquired a new position in Senti Biosciences during the 3rd quarter valued at about $117,000. Virtu Financial LLC acquired a new stake in shares of Senti Biosciences during the 4th quarter worth approximately $46,000. Finally, Jane Street Group LLC acquired a new position in Senti Biosciences in the fourth quarter valued at approximately $40,000. Institutional investors own 25.70% of the company’s stock.

About Senti Biosciences

Senti Biosciences (NASDAQ:SNTI) is a clinical-stage synthetic biology company focused on engineering next-generation cell therapies. The company’s platform leverages modular genetic circuits to sense disease signals and precisely control cellular functions, with the goal of improving safety and efficacy in oncology and immune-mediated diseases.

Senti’s core technologies include its SENTINEL circuit platform and SNIP receptor system, which enable programmable sensing of molecular cues and context-dependent payload release.